Infinata’s BioPharm Clinical™ Incorporates Massive New Data Sets to Enhance Trial Analytics Throughout EMEA

Share Article

Provides subscribers with full access to 16,500 EMEA trials with comprehensive investigator, site, indication and patient pool analysis

The industry’s most comprehensive solution for global study feasibility and site selection support just got better. Infinata’s BioPharm Clinical™ has integrated massive data sets from EudraCT to complement existing sources (including ten international regulatory institutions) to provide subscribers with full access to all 16,500 trials throughout EMEA.

This significant influx of data will further enable subscribers to:

  • Search an enormous pool of EMEA trials by phase, endpoints, inclusion/exclusion criteria, sites and more
  • Generate custom reports to capture a complete picture of clinical activity in EMEA by indication and country

“We are excited to increase our European clinical coverage for our valued clients,” said Ruth McHenry, Managing Director of Infinata. “The most important benefits will be realized in our thorough analytics section with expanded analysis of European registered trials.”

This allows clients to more reliably assess which investigators have the proven success meeting enrollment targets for similar trials, and identify ideal patient population profiles in regions that aren’t currently recruiting for the given indication.

For more details on BioPharm Clinical including the new EMEA trial data, schedule a personalized online demonstration at

About BioPharm Clinical
BioPharm Clinical is an exclusive support solution for clinical operations professions, providing real-time trial analytics and the most comprehensive database of sites and investigators. Clients benefit from proprietary calculations tailored to their particular trial requirements, detailed milestone timelines and more as they make critical study feasibility assessments and evaluate investigators for their global programs. Learn more at

About Infinata, Inc.
Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. Find more information at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kristopher Sarajian
Email >
Visit website